Dr Julian Adams (Gamida Cell) at ASH17

After exploring what NK cells are, what they do and the clinical perspectives of three academic thought leaders active in reseach in this niche, it’s time for something different.

We now turn our attention to companies with R&D pipelines focused on developing NK cell based therapeutics.

One biotech company of interest here is Gamida Cell, who are developing cellular and immune therapeutics.

In a recent fireside chat with CEO Dr Julian Adams, we learned more about what they are doing and more importantly, where they are heading…

To learn more from our latest biotech C-suite interview and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by